Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/58634
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
Author: Galanopoulos, A.
Goldberg, I.
Citation: Clinical Ophthalmology (online), 2009; 3(1):117-122
Publisher: Dove Medical Press
Issue Date: 2009
ISSN: 1177-5483
1177-5483
Statement of
Responsibility: 
Anna Galanopoulos and Ivan Goldberg
Abstract: Elevated intraocular pressure (IOP) is a significant risk factor for the development and progression of glaucomatous optic neuropathy, but increasingly we appreciate that non-pressure dependent factors, are key to our understanding of the pathophysiology of these neurodegenerative diseases, that target the retinal ganglion cell. As we try to expand therapy beyond IOP control, medications are being assessed for their neuroprotective abilities. Brimonidine is an effective ocular hypotensive treatment both as a first and second line agent, in the management of glaucoma and ocular hypertension. Brimonidine tartrate 0.2% is generally safe and well tolerated, with its safety profile further enhanced in the altered formulation brimonidine-Purite™ 0.1%. Beyond brimonidine’s pressure lowering capacity, laboratory and early clinical evidence supports its neuroprotective potential. We await validation of this in human clinical trials.
Keywords: brimonidine; neuroprotection; clinical effectiveness; tolerability
Rights: © 2009 Galanopoulos and Goldberg, publisher and licensee Dove Medical Press Ltd. This is an OpenAccess article which permits unrestricted noncommercial use, provided the original work is properly cited.
RMID: 0020096722
DOI: 10.2147/OPTH.S3270
Appears in Collections:Opthalmology & Visual Sciences publications

Files in This Item:
File Description SizeFormat 
hdl_58634.pdf77.31 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.